Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/33278
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHoldsworth S.R.en
dc.contributor.authorTipping P.G.en
dc.contributor.authorKitching A.R.en
dc.date.accessioned2021-05-14T11:17:07Zen
dc.date.available2021-05-14T11:17:07Zen
dc.date.copyright2000en
dc.date.created20000919en
dc.date.issued2012-10-20en
dc.identifier.citationCurrent Opinion in Nephrology and Hypertension. 9 (5) (pp 505-511), 2000. Date of Publication: 2000.en
dc.identifier.issn1062-4821en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/33278en
dc.description.abstractIncreased understanding of the fundamental importance of the role of chemokines and their receptors in inflammation, together with the demonstration of their involvement in human and experimental inflammatory renal disease, make these molecules potential therapeutic targets. A number of recent studies using genetically deficient mice and chemokine receptor antagonists in animal models have demonstrated that chemokine inhibition can attenuate experimental renal injury. Because there is simultaneous expression of multiple chemokines and receptors in disease, strategies that are aimed at antagonizing multiple chemokines receptor interactions are likely to be more effective than therapies that target a single chemokine. It is also now recognized that chemokines are involved in normal immune development and immune regulation. These observations, together with the results of studies that have demonstrated deleterious effects of chemokine receptor antagonism in experimental renal disease, highlight the need for thorough understanding of the role of individual chemokines in the pathogenesis of different types of renal disease before optimal therapeutic interventions may be achieved. (C) 2000 Lippincott Williams and Wilkins.en
dc.languageenen
dc.languageEnglishen
dc.publisherLippincott Williams and Wilkins (250 Waterloo Road, London SE1 8RD, United Kingdom)en
dc.titleChemokines as therapeutic targets in renal disease.en
dc.typeReviewen
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1097/00041552-200009000-00008en
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid10990369 [http://www.ncbi.nlm.nih.gov/pubmed/?term=10990369]en
dc.identifier.source30677028en
dc.identifier.institution(Holdsworth, Kitching, Tipping) Monash University, Department of Medicine, Monash Medical Centre, 246 Clayton Rd., Clayton, Vic., Australia (Holdsworth) Monash University, Department of Medicine, Monash Medical Centre, 246 Clayton Rd., Clayton, Vic. 3168, Australiaen
dc.description.addressS.R. Holdsworth, Monash Univ. Department of Medicine, Monash Medical Centre, 246 Clayton Rd, Clayton, Vic. 3168, Australia. E-mail: steven.holdsworth@med.monash.edu.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2012 Elsevier B.V., All rights reserved.en
dc.identifier.authoremailHoldsworth S.R.; steven.holdsworth@med.monash.edu.auen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeReview-
crisitem.author.deptImmunology and Allergy-
crisitem.author.deptNephrology-
Appears in Collections:Articles
Show simple item record

Page view(s)

28
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.